Cancer is the second most common cause of death in the USA. Among the known classes of anticancer agents, the microtubule-targeted antimitotic drugs are considered to be one of the most important. They are usually classified into microtubule-destabilizing (e.g., Vinca alkaloids) and microtubule-stabilizing (e.g., paclitaxel) agents. Combretastatin A4 (CA-4), which is a natural stilbene isolated from Combretum caffrum, is a microtubule-destabilizing agent that binds to the colchicine domain on β-tubulin and exhibits a lower toxicity profile than paclitaxel or the Vinca alkaloids. In this paper, we describe the docking study, synthesis, antiproliferative activity and selectivity index of the N-acylhydrazone derivatives (5a–r) designed as CA-4 analogues. The essential structural requirements for molecular recognition by the colchicine binding site of β-tubulin were recognized, and several compounds with moderate to high antiproliferative potency (IC50 values ≤18 μM and ≥4 nM) were identified. Among these active compounds, LASSBio-1586 (5b) emerged as a simple antitumor drug candidate, which is capable of inhibiting microtubule polymerization and possesses a broad in vitro and in vivo antiproliferative profile, as well as a better selectivity index than the prototype CA-4, indicating improved selective cytotoxicity toward cancer cells.
References
[1]
Nogales E (2000) Structural insights into microtubule function. Annual Review of Biochemistry 69: 277–302.
[2]
Desai A, Mitchison TJ (1997) Microtubule polymerization dynamics. Annual Review of Cell and Development Biology 13: 83–117. doi: 10.1146/annurev.cellbio.13.1.83
[3]
Singh P, Rathinasamy K, Mohan R, Panda D (2008) Microtubule Assembly Dynamics: An attractive target for anticancer drugs. IUBMB Life 60: 368–375. doi: 10.1002/iub.42
[4]
Jordan MA, Wilson L (2004) Microtubule as a target for anticancer drugs. Nature Reviews: Cancer 4: 253–263. doi: 10.1038/nrc1317
[5]
Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E (2001) The binding conformation of taxol in β-tubulin: a model based on electron crystallographic density. Proceeding of the National Academy of Sciences of United States of America 98: 5312–5316. doi: 10.1073/pnas.051309398
[6]
Prisen VE, Honess DJ, Stratford MR, Wilson J, Tozer GM (2002) The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4 phosphate, at clinically relevant dose. Int. J. Oncology 21: 717–726. doi: 10.3892/ijo.21.4.717
[7]
Fürst R, Zupkó I, Beréyi A, Ecker GF, Rinner U (2009) Synthesis and antitumor evaluation of cyclopropyl-containing combretastatin analogs. Bioorganic & Medicinal Chemistry Letters 19: 6948–6951. doi: 10.1016/j.bmcl.2009.10.064
[8]
Tron GC, Pirali T, Sorba G, Francesca P, Busacca S, et al. (2006) Medicinal Chemistry of combretastatin A-4: Present and future directions. Journal of Medicinal Chemistry 49: 3033–3044. doi: 10.1021/jm0512903
[9]
Shan Y, Zhang J, Liu Z, Wang M, Dong Y (2011) Developments of combretastatin A-4 derivatives as anticancer agents. Current Medicinal Chemistry 18: 523–538. doi: 10.2174/092986711794480221
[10]
Lee L, Robb LM, Lee M, Davis R, Mackay H, et al. (2010) Design, synthesis and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazolin？eanalogs of combretastatin-A4. Journal of Medicinal Chemistry 53: 325–334. doi: 10.1021/jm901268n
[11]
Combes S, Barbier P, Douillar S, McLeer-Florin A, Bourgarel-Rey V, et al. (2011) Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastains. Part 2. Journal of Medicinal Chemistry 54: 3153–3162. doi: 10.1021/jm901826e
[12]
Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, et al. (2004) Insight into tubulin regulation from a complex with colchicines and stathmin-like domain. Nature 428: 198–202. doi: 10.1038/nature02393
[13]
Bai R, Covell DG, Pei XF, Ewell JB, Nguyen NY, et al. (2000) Mapping the Binding site of colchinoids on β-tubulin. The Journal of Biological Chemistry 275: 40443–40452. doi: 10.1074/jbc.m005299200
[14]
Ducki S, Forrest R, Hadfield JA, Kendall A, Lawrence NJ, et al. (1998) Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorganic & Medicinal Chemistry Letters 8: 1051–1056. doi: 10.1016/s0960-894x(98)00162-0
[15]
Ducki S, Rennison D, Woo M, Kendall A, Chabert JFD, et al. (2009) Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part-1: Synthesis and biological evaluation of antivascular activity. Bioorganic & Medicinal Chemistry 17: 7698–7710. doi: 10.1016/j.bmc.2009.09.039
[16]
Ducki S, Mackenzie G, Greedy B, Armitage S, Charbert JFD, et al. (2009) Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part-2: structure-based of alpha-aryl chalcones. Bioorganic & Medicinal Chemistry 17: 7711–7722. doi: 10.1016/j.bmc.2009.09.044
[17]
Wermuth GC (2008) The Practice of Medicinal Chemistry, Thirth edition. Academic Press. pp. 448–452.
[18]
Dorléans A, Gigant B, Ravelli RBG, Mailliet P, Mikol V, et al. (2009) Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proceeding of the National Academy of Sciences of United States of America 33: 13775–13779. doi: 10.1073/pnas.0904223106
[19]
Lima PC, Lima LM, da Silva KCM, Léda PHO, Miranda ALP, et al. (2000) Synthesis and analgesic activity of novel N-acylhydrazones and isosters, derived from natural safrole. European Journal of Medicinal Chemisty 35: 187–203. doi: 10.1016/s0223-5234(00)00120-3
[20]
Farrugia LJ (1997) Ortep-3 for windows – a variation of Ortep III with a graphical user interface. Journal of Applied Crystallography 30: 565–566. doi: 10.1107/s0021889897003117
[21]
Mosman T (1983) Rapid Colorimetric Assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65: 55–63. doi: 10.1016/0022-1759(83)90303-4
[22]
Jin L, Chen J, Song B, Chen Z, Yang S, et al. (2006) Synthesis, structure, and bioactivity of N′-substituted benzylidene-3,4,5-trimethoxybenzohydrazi？deand 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-di？hydro-1,3,4-oxadiazolederivatives. Bioorganic and Medicinal Chemistry Letters 16: 5036–5040. doi: 10.1016/j.bmcl.2006.07.048
[23]
Kümmerle AE, Raimundo JM, Leal CM, da Silva GS, Balliano TL, et al. (2009) Studies towards the identification of putative bioactive conformation of potent vasodilatador arylidene N-acylhydrazone derivatives. European Journal of Medicinal Chemistry 44: 4004–4009. doi: 10.1016/j.ejmech.2009.04.044
[24]
Yogeeswari P, Sriram D, Thirumurugan R, Raghavendran JV, Sudhan K, et al. (2005) Discovery of N- (2,6- dimethylphenyl)- substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. Journal of Medicinal Chemistry 48: 6202–6211. doi: 10.1021/jm050283b
[25]
Hollingshed MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, et al. (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sciences 57: 131–141. doi: 10.1016/0024-3205(95)00254-4
[26]
Hall LA, Krauthauser CM, Wexler RS, Hollingshed MG, Slee AM, et al. (2000) The Hollow Fiber assay: Continued characterization with novel approaches. Anticancer Research 20: 903–911.
[27]
Sadar MD, Akopian VA, Beraldi E (2002) Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Molecular Cancer Therapies 1: 629–637.
[28]
Suggitt M, Swaine DJ, Petit GR, Bibby MC (2004) Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo. Clinical Cancer Research 10: 6677–6685. doi: 10.1158/1078-0432.ccr-04-0855
[29]
Cao X, Wang Y, Li S, Chena C, Ke S (2011) Synthesis and biological activity of a series of novel N-substituted lactams derived from natural gallic acid. Journal of Chinese Chemical Society 58: 35–40. doi: 10.1002/jccs.201190055
[30]
Mazzone G, Bonina F, Formica F (1978) Su alcuni aroilidrazoni di alogenobenzaldeidi e 2,5-diarial-1,3,4-ossadiazoli alogeno-sostituiti. Il Farmaco – Ed. Scientifica 33: 963–971.
[31]
Borchhardt DM, Mascarello A, Chiaradia LD, Nunes RJ, Oliva G, et al. (2010) Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanossoma cruzi. Journal of Brazilian Chemical Society 21: 142–150. doi: 10.1590/s0103-50532010000100021
[32]
Mazzone G, Reina R (1991) 3,4,5-trimetossibenzoil idrazidi ad attività IMAO. Bolletino delle Sedute della academia gionia di scienze naturali in Catania 8: 689–702.
Andrade MM, Barros MT (2010) Fast synthesis of N-acylhydrazones employing a microwave assisted neat protocol. Journal of Combinatorial Chemistry 12: 245–247. doi: 10.1021/cc9001444
[35]
Mack CH, McGregor HH, Hobart SR (1969) Synthesis of some phenyl N-aroyl carbamates. Journal of Engineering data 14: 258–261. doi: 10.1021/je60041a042
[36]
Sheldrick GM (2008) A Short history of SHELX. Acta Crystallographica Section A 64: 112–122. doi: 10.1107/s0108767307043930
[37]
Farrugia LJ (1999) WinGX suite for small-molecule single-crystal crystallography. Journal of Applied Crystallography 32: 837–828. doi: 10.1107/s0021889899006020
[38]
Schneider P, Hosseiny SS, Szczotka M, Jordan V, Shlitter K (2009) Rapid solubility determination of the triterpenes oleanoic acid and ursolic acid by UV-spectroscopy in different solvents. Phytochemistry Letters 2: 85–87. doi: 10.1016/j.phytol.2008.12.004
[39]
Bonne D, Heusèle C, Simon C, Pantaloni D (1985) 4′,6-Diamino-2-phenylindole, a fluorescent probe for tubulin and microtubules. The Journal of Biological Chemistry 260: 2819–2825.
[40]
United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the welfare of animals in experimental neoplasia (second edition). British Journal of Cancer 77: 1–10.
[41]
Directive 86/609/EEC. Council Directive of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes.
[42]
Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP (1998) Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. Journal of American Chemical Society 107: 3902–3909. doi: 10.1021/ja00299a024
[43]
Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. the development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. Journal of Computer-Aided Molecular Design 11: 425–445.
[44]
Baxter CA, Murray CW, Clark CE, Westhead DR, Eldridge MD (1998) Flexible docking using tabu search and an empirical estimate of binding affinity Proteins: Structure,. Function and Bioinformatics 33: 367–382. doi: 10.1002/(sici)1097-0134(19981115)33:3<367::aid-prot6>3.0.co;2-w
